When was Third Harmonic Bio founded?

Third Harmonic Bio was founded in 2019 and raised its 1st funding round within a year of its incorporation.

Where is Third Harmonic Bio located?

Third Harmonic Bio is headquartered in Cambridge, United States. It is registered at Cambridge (United States).

How many employees does Third Harmonic Bio have?

As of Sep 30, 2026, the latest employee count at Third Harmonic Bio is 7.

Is Third Harmonic Bio a funded company?

Third Harmonic Bio is a funded company, having raised a total of $205M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jan 2019.

When was the latest funding round of Third Harmonic Bio?

Third Harmonic Bio's latest funding was a $***** Series B round on Feb 16, 2022, with participation from 8 investors.

Where does Third Harmonic Bio rank among its competitors?

Third Harmonic Bio ranks 618th amongst 2990 active competitors, of which 975 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Third Harmonic Bio?

Third Harmonic Bio's top competitors include Jazz Pharmaceuticals, BeiGene and Biogen. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Third Harmonic Bio - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer therapeutics to treat allergy and inflammatory diseases. The company's product line include THB001 is an oral small-molecule KIT inhibitor for the treatment of severe allergic and mast cell-driven inflammatory conditions like Chronic Inducible Urticaria, airway, and gastrointestinal tract indications.

Website: thirdharmonicbio.com
Social
Email ID: *****@thirdharmonicbio.com
Registered Address: Cambridge (United States)

Key Metrics

Founded Year

2019

Location

Cambridge, United States

Stage

Public

Total Funding

$205M in 3 rounds

Latest Funding Round

Series B, Feb 16, 2022, $*****

Investors

Atlas Venture & 10 more

Ranked

618^th among 2990 active competitors

Employee Count

7 as on Sep 30, 2026

Similar Companies

BeiGene & 700 more

Exit Details

Public

View Third Harmonic Bio's full profile

Third Harmonic Bio is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
THIRD HARMONIC BIO, INC. CIN: 1923840 , United States, Active	Apr 24, 2019	-	-	-
Third Harmonic Bio, Inc. CIN: 83-4553503 , United States, Active	Dec 31, 2018	-	28 (As on Dec 31, 2022)	-

Third Harmonic Bio got listed on Sep 15, 2022.

Click here to take a look at Third Harmonic Bio's IPO in detail

Third Harmonic Bio has raised a total funding of $205M over 3 rounds. Its first funding round was on Jan 2019. Its latest funding round was a Series B round on Feb 16, 2022 for $*****. 8 investors participated in its latest round. Third Harmonic Bio has 11 institutional investors.

Here is the list of recent funding rounds of Third Harmonic Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 16, 2022	1751829	Series B	1538698	9300152	6919064	7269700
2019	4776	Series A	3523	2698	9788	BVF Partners
Jan 2019	6859164	Seed	2877123	3864479	9311418	Atlas Venture

Access funding benchmarks and valuations. Sign up today!

View details of Third Harmonic Bio's funding rounds and investors

Third Harmonic Bio's employee count trend

Third Harmonic Bio has 7 employees as of Sep 26. Here is Third Harmonic Bio's employee count trend over the years:

Employee count trend for Third Harmonic Bio

Uncover Third Harmonic Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Third Harmonic Bio include Jazz Pharmaceuticals, BeiGene and Biogen. Here is the list of Top 10 competitors of Third Harmonic Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
4th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
5th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
7th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
8th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
618th	Third Harmonic Bio 2019, Cambridge (United States), Public	Developer therapeutics to treat allergy and inflammatory diseases	$205M	Bain Capital Life Sciences, BVF Partners & 9 others	42/100